Cancers & treatments·Regimen libraryFirst line

CVP (with rituximab, R-CVP)

Checked 2026-09-09

Follicular and other indolent B-cell lymphomas needing treatment, when an anthracycline is not wanted

Also called CVP, R-CVP.

One cycle

every 21 days × 8 · about 24 weeks in total

21-day cycle × 8 (about 24 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days
Rituximab Monoclonal antibody (anti-CD20, chimeric)	375 mg/m² (R-CVP)	IV	D1
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	750 mg/m²	IV	D1
Vincristine Vinca alkaloid (microtubule inhibitor)	1.4 mg/m² (maximum 2 mg)	IV	D1
Prednisone Glucocorticoid	40 mg/m² once daily	Oral	D1-5

Cycles

21-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

Adding rituximab to CVP improved response and time to treatment failure; bendamustine-rituximab has since displaced R-CVP for many patients.

Used in

Follicular lymphoma

Products

RituximabCyclophosphamideVincristinePrednisone

Source

Marcus, Blood 2005: R-CVP versus CVP in follicular lymphoma

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

R-CHOP

Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)

every 21 days × 6

Bendamustine + rituximab (BR)

Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable

every 28 days × 6

Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T

Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma

every 6 days

All regimens ICE →